BioNTech SE American Depositary Share

BNTX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
BNTX Income Statement
BNTX Balance Sheet
BNTX Cash Flow
Congress Trading

Recent trades of BNTX by members of U.S. Congress

Politician Type Traded
Josh Gottheimer House / D Sale $1,001 - $15,000 Sep. 03, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Aug. 30, 2024
Josh Gottheimer House / D Purchase $1,001 - $15,000 Apr. 15, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Mar. 14, 2024
Josh Gottheimer House / D Purchase $1,001 - $15,000 Dec. 07, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Dec. 06, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Dec. 05, 2023
BNTX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
BNTX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
BNTX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by BNTX's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Formulation for administration of rna Nov. 26, 2024
  • Patent Title: Coronavirus vaccine Nov. 05, 2024
  • Patent Title: Preparation and storage of liposomal rna formulations suitable for therapy Aug. 13, 2024
  • Patent Title: Stabilization of poly(a) sequence encoding dna sequences Aug. 06, 2024
  • Patent Title: Substituted imidazoquinolines Aug. 06, 2024
  • Patent Title: Substituted imidazoquinolines as agonists of tlr7 May. 21, 2024
  • Patent Title: Rna constructs and uses thereof Apr. 09, 2024
  • Patent Title: Monoclonal antibodies directed against programmed death-1 protein and their use in medicine Mar. 19, 2024
  • Patent Title: Coronavirus vaccine Mar. 12, 2024
  • Patent Title: Methods for characterizing loss of antigen presentation Mar. 05, 2024
  • Patent Title: Coronavirus vaccine Jan. 23, 2024
  • Patent Title: Method for reducing immunogenicity of rna Jan. 16, 2024
  • Patent Title: Nucleic acid molecules encoding binding agents to cd40 and 4-1bb (cd137) Nov. 14, 2023
  • Patent Title: Diagnosis and therapy of cancer involving cancer stem cells Oct. 24, 2023
  • Patent Title: Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases Oct. 17, 2023
  • Patent Title: Rna constructs and uses thereof Oct. 10, 2023
  • Patent Title: Human monoclonal antibodies to ganglioside gd2 Sep. 19, 2023
  • Patent Title: Rna for treatment of autoimmune diseases Jul. 18, 2023
  • Patent Title: Particles comprising a shell with rna May. 30, 2023
  • Patent Title: Coronavirus vaccine Jan. 10, 2023
  • Patent Title: Individualized vaccines for cancer Nov. 22, 2022
  • Patent Title: 3′-utr sequences for stabilization of rna Nov. 08, 2022
  • Patent Title: Methods and compositions for stimulating immune response Oct. 18, 2022
  • Patent Title: Preparation and storage of liposomal rna formulations suitable for therapy Jul. 26, 2022
  • Patent Title: Formulation for administration of rna May. 03, 2022
  • Patent Title: Recombinant vaccines and use thereof Apr. 12, 2022
  • Patent Title: Predicting immunogenicity of t cell epitopes Jan. 11, 2022
  • Patent Title: Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof Jun. 29, 2021
  • Patent Title: Cytotoxic immunostimulating particles and uses thereof Apr. 20, 2021
  • Patent Title: Agonistic tumor necrosis factor (tnf) receptor binding agents Feb. 23, 2021
  • Patent Title: Particles comprising protamine and rna in combination with endosome destabilizing agents Aug. 04, 2020
  • Patent Title: Agents for treatment of claudin expressing cancer diseases Jul. 21, 2020
  • Patent Title: Hydrogen water generator May. 26, 2020
  • Patent Title: Methods of inducing t cell activation by administering an antibody comprising cd40 and 4-1bb (cd137) binding domains Oct. 29, 2019
  • Patent Title: Compositions and methods for diagnosis and treatment of cancer Aug. 06, 2019
  • Patent Title: Identification of surface-associated antigens for tumor diagnosis and therapy May. 28, 2019
  • Patent Title: Identification of tumor-associated markers for diagnosis and therapy Apr. 09, 2019
  • Patent Title: Tumor antigens for determining cancer therapy Jan. 29, 2019
  • Patent Title: Particles comprising single stranded rna and double stranded rna for immunomodulation Jan. 08, 2019
  • Patent Title: Modification of rna, producing an increased transcript stability and translation efficiency Oct. 23, 2018
  • Patent Title: Agents for treatment of claudin expressing cancer diseases Oct. 09, 2018
  • Patent Title: Site-specific antibody-mediated activation of proapoptotic cytokines: amaize (antibody-mediated apoptosis inducing cytokines) Apr. 17, 2018
  • Patent Title: Identification of tumor-associated cell surface antigens for diagnosis and therapy Mar. 06, 2018
  • Patent Title: Homo- and heterodimeric smac mimetic compounds as apoptosis inducers Aug. 15, 2017
  • Patent Title: Genetic products differentially expressed in tumors and use thereof May. 02, 2017
  • Patent Title: Particles comprising single stranded rna and double stranded rna for immunomodulation May. 02, 2017
  • Patent Title: Identification of surface-associated antigens for tumor diagnosis and therapy Jan. 03, 2017
  • Patent Title: Use of flt3 ligand for enhancing immune responses in rna immunization Nov. 08, 2016
  • Patent Title: Modification of rna, producing an increased transcript stability and translation efficiency Oct. 25, 2016
  • Patent Title: Homo- and heterodimeric smac mimetic compounds as apoptosis inducers Apr. 26, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of BNTX in WallStreetBets Daily Discussion

BNTX News

Recent insights relating to BNTX

CNBC Recommendations

Recent picks made for BNTX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BNTX

BNTX Top Shareholders
Shareholder
Shares Held
BNTX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

BNTX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view BNTX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top